1. Alpha-1 Antitrypsin Deficiency in COPD

2. This program will include a discussion of off-label treatment not approved by the FDA for use in the US.

3. The Discovery of AATD

4. What Causes AATD?

5. Diseases Associated With AATD

6. A1AT: The Protective Protein

7. Panlobular Emphysema Caused by AATD

8. A1AT Levels by Phenotype

9. A1AT Protective Threshold Level

10. Who Should Be Screened?

11. What Should Be Tested?

12. Conventional Treatment: COPD

13. Conventional Treatment: COPD (cont)

14. Conventional Treatment: COPD (cont)

15. Preventing Liver Disease

16. A1AT Augmentation Therapy

17. AATD Registry Study Group

18. AATD Registry Study: FEV1 Decline

19. Observational Studies: Clinical Implications

20. RAPID Trial

21. RAPID-OLE: Decline in Adjusted Lung Density

22. RAPID: Dosing

23. RAPID: Achieved A1AT Levels and Lung Density

24. RAPID: 6-Year Projected Life Extension With Augmentation Therapy

25. RAPID: Measuring Treatment Efficacy

26. RAPID: IDES/DES Biomarkers

27. RAPID: Potential of IDES/DES Biomarkers

28. Efficacy of Augmentation Therapy: Consistent Across Clinical Trials

29. Key Takeaways

30. Abbreviations

31. Abbreviations (cont)